#CRCTrialsChat

Let's learn about CRC #Clinicaltrials
Patients, caregivers, clinicians, patient advocates: All are welcome!

Volunteer activity organized by @manjuggm

[#CRCTrialsChat @CrcTrialsChat]

Everyone with #EarlyOnsetCRC wants to know why they were diagnosed with #colorectalcancer..

This month's #CRCTrialsChat #VideoShorts on the @CancerGrand #PROSPECT project explores this question

Let's hear from the PIs, Dr. @AndyChanMD & Dr. @yincaoScD! See you tomorrow!
#CRCSM

[Manju George MVSc PhD @manjuggm]

@TheMSCCRT Excited to launch the #MS80By2030 #CRCScreening campaign focused on Mississippians ages 45-59. Because if we can get these folks screened, hopefully they will continue to stay screened!
@NCCRTnews #TowardsAHealthierMississippi

[Fight Colorectal Cancer @FightCRC]

Call-on Congress is evolving, and global researchers are joining the fight against early-onset #colorectalcancer.
Learn what's changing, why it matters, and how advocates can help drive progress at our next Advocacy Action Hour. Register now at https://t.co/ATsr5hdFRo

[OncoDaily @oncodaily]

@FcancerAK
@womenofteal
@vevshughes
@KatreceNolen
@annmcbrien_
@itsnot_pink
@MyelomaTeacher @HealthTree
@PaulaMaier3
@hilmoss @OncoveryCare
@lysabee
@manjuggm @CRCTrialsChat
@LisaAcquaviva2
@bjork5 @medidata @CeiFCCC
@MucosalMelanoma
@DuchessLizzy2

[Pashtoon Kasi MD, MS @pashtoonkasi]

#AACR26 Excited & honored to unveil initial results from the phase-2 CLOVER ☘️ trial.

CCR5-targeting
Leronlimab with
Oral chemotherapy &
VEGF-inhibitor
Enriched
Regimen

🏃‍♂️to our session
🔖 2-5PM
📍Section41🪧Poster14

👇🏽Promising #ctDNA💦📉
MSS #ColorectalCancer

@OncoA@OncoAlert

[Smitha Krishnamurthi @smitha42]

Short term data but incredible

[Dr. Nina Niu Sanford @NiuSanford]

Thank you, @chadinabhan for having me on your pod.

Enjoyed talking all things GI rad onc with you!

[Sarbajit Mukherjee @Sarbaji85064063]

Huge congratulations to @waraonc23 and Dr. Takahashi on their presentations at the @AACR annual meeting.

Obesity shaping CRC biology + immune checkpoints, and consistent irAE rates with ICIs across populations—both highly relevant, impactful work.

Great working with them on these projects. More to come soon in publications.

@RoswellPark @RoswellHemOnc @Deebacca @MiamiCancerInst @BHCancerCare @BaptistHealthSF

[Van Morris, MD @VanMorrisMD]

🙏@AACR for inviting me to talk re pt-centric approaches for oral therapies in CRC. Always happy to highlight our @UTMDAnderson CRC team using ctDNA & novel trial design to bring best & safest to our pts, led by the incredible @JarettFeldmanMD, @vserpashigbie & Dr Alisha Bent!

[Nicholas Hornstein @GIMedOnc]

Drug development is supposed to be linear.

Build the drug → use the drug → resistance shows up → then figure out what to do next.

Aaaand not what Revolution Medicines is doing. 🧬

At #AACR26 they disclosed RM-055, which honestly is a unique concept.

Before daraxonrasib is even fully in the world, they’re building around resistance.

How it works:

• Most mutant RAS proteins are relatively resistant to GAP-mediated hydrolysis
• That helps keep RAS in the active state
• They’ve found a way to enhance that hydrolysis with RM-055

RM-055 can:
• restore hydrolysis in mutant RAS
• flatten daraxonrasib-resistant models
• generate activity even in RAS-amplified settings 👀

That’s a very smart way to think about this space.

Not just “here’s our inhibitor.”

More like: we already know resistance to our drug is coming, so let’s start building now.

That’s how we cure cancer, not more me-toos (if I hear about another new PD1 program I’m going to cry).

@OncoAlert @TheGutOncLab @Onco_Nexus

[Jill Feldman @jillfeldman4]

Thank you, @AACR, for giving advocates a place to learn, ask questions, grow, and foster collaborations with scientists and other advocates. Your belief that we belong in these spaces has empowered us, helped us find our voices, and contributed in meaningful ways. #AACR26

[Manju George MVSc PhD @manjuggm]

This is exciting!! I have always wanted to know the biomarker profile of folks without a cCR after TNT Perhaps combining biomarker directed therapies with SOC chemo as TNT is the next step to increase cCR rates and NOM for locally advanced rectal cancer Need #NCTN trials here!

[MSCCRT @TheMSCCRT]

Mississippi has one of the highest colorectal cancer rates in the U.S.
Screening saves lives.
#ScreenAt45
#TowardsAHealthierMississippi
#CRCSM
#GetScreened!

[Manju George MVSc PhD @manjuggm]

March is #ColorectalCancerAwareness Month 💙

When I was diagnosed with rectal cancer, everything changed overnight

Even with a science background, nothing prepares you emotionally for hearing the word “cancer.”

If you’re going through this, you are not alone
#CRCSM @colontown

[COLONTOWN @colontown]

Fresh off an incredible #GI26. 💙 The COLONTOWN team was proud to present a poster on 5-FU Freedom (via pump self-disconnect), work that grew directly from patient-to-patient convos in our Community!

👉 If you self-disconnect your 5-FU pump, comment with your cancer center.

[Jame Abraham, MD, FACP @jamecancerdoc]

Congratulations @VanitaNoronha and @TataMemorial team for asking really important questions about the right dose and duration of immunotherapy! We need to address over treatment !! @OncoAlert !

[Vanita Noronha, MBBS MD DM @VanitaNoronha]

What if we’ve been overdosing immunotherapy all along?
In our Ph III DELII study, 20 mg nivolumab q2w beat chemo in OS, with less toxicity, better QoL. It's time to rethink ICI dosing-for science and equity! https://t.co/mBqq2sdm6v @JCO_ASCO @OncoAlert @TataMemorial @SuyogCancer

[Fight Colorectal Cancer @FightCRC]

Incredibly grateful to Andy Chan for presenting our global #EOCRC Think Tank efforts at the #SU2CInnovationSummit. Grateful for the opportunity to highlight this collaborative, international work advancing #colorectalcancerresearch. #cancerresearch @SU2C
Learn more about our #GEOCRCTT: https://t.co/SyaTQsexPZ

[Nicholas Hornstein @GIMedOnc]

I’ve seen alot of posts recently about pancreatic cancer being “cured” in mice. Just a general reminder of something that is currently hung in my office:

[OncoAlert @OncoAlert]

TODAY February 4, 2026: The 6th Annual OncoAlert Colloquium 🚨GI Malignancies
REGISTER👉 https://t.co/g9QBl5RGsQ

GI Day 3 Feb 4, 2026
As ALWAYS ✅Patients Included

@BenWestphalen 🇩🇪
@GIMedOnc 🇺🇸
@Graokane 🇮🇪
@NiuSanford 🇺🇸
@realbowtiedoc 🇺🇸
@ARosen380 🇺🇸
@Erman_Akkus 🇹🇷
John Herrera Kok🇪🇸
Marco Inama 🇮🇹

@pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago

Our Partners
@ESGO_society @ESSOnews @CancerCareMASCC @SIOGorg

[OncoAlert @OncoAlert]

The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE
Presentation by Dr. Nicholas Hornstein🇺🇸 of Northwest Health: Year in Review Upper GI
REGISTER HERE TO WATCH: https://t.co/wpGIQQTUYq

🚨 Practice-changing science in 2025: Upper GI Oncology 🚨

🔹 MATTERHORN🏔️ : Adding perioperative durvalumab to FLOT significantly improves outcomes in resectable gastric/GEJ cancer — marking immunotherapy’s entry into the curative-intent setting for fit, resectable disease.

🔹 DESTINY-Gastric04: Trastuzumab deruxtecan (T-DXd) clearly outperforms ramucirumab-based therapy in 2L HER2+ GEJ, confirming T-DXd as the preferred second-line standard after trastuzumab exposure. 🎯
🔹 HORIZON-GEA-01: Zanidatamab + chemo outperforms trastuzumab-based regimens in 1L HER2+ metastatic GEJ, establishing dual-HER2 blockade as the new frontline backbone.

2025 is reshaping the treatment paradigm in upper GI cancer — more targeted, more effective, and more personalized than ever. #UpperGI #Oncology #GastricCancer #HER2

@BenWestphalen 🇩🇪
@GIMedOnc 🇺🇸
@Graokane 🇮🇪
@NiuSanford 🇺🇸
@realbowtiedoc 🇺🇸
@ARosen380 🇺🇸
@Erman_Akkus 🇹🇷
John Herrera Kok🇳🇱
Marco Inama 🇮🇹

@pashtoonkasi @marklewismd @AndresC27622123 @manjuggm @stacy_hurt @KoheiShitara @GillSharlene @FLordick28391

#OncoAlertAF
@nataliagandur @acampsmalea @BRicciutiMD
@HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK
@MarioBalsaMD @DrMirallas @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88 @PaulJiL @DaisukeKotani @DraMartinezLago